23 results
8-K
EX-99.1
KPTI
Karyopharm Therapeutics Inc
8 May 24
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
7:47am
treatments.
R&D Highlights
Endometrial Cancer
Invited to present updated long-term follow-up data of selinexor in patients with TP53 wild-type advanced … and development (R&D) expenses: R&D expenses for the first quarter of 2024 were $35.4 million, compared to $32.3 million for the first quarter of 2023
8-K
EX-99.1
KPTI
Karyopharm Therapeutics Inc
29 Feb 24
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
7:35am
potential.”
Fourth Quarter 2023 and Recent Highlights
Research and Development (R&D) Highlights
Long-term exploratory analysis of the pre-specified … of $100 million to $120 million.
R&D and SG&A expenses to be in the range of $260 million to $280 million, which includes approximately $20 million
8-K
EX-99.1
KPTI
Karyopharm Therapeutics Inc
2 Nov 23
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
7:37am
received one-to-three prior lines of therapy in the September 2023 Clinical Practice Guidelines in Oncology.
R&D Highlights
Myelofibrosis
Data from … royalties on net product revenue.
Research and development (R&D) expenses: R&D expenses for the third quarter of 2023 were $35.6 million, compared
8-K
EX-99.1
KPTI
Karyopharm Therapeutics Inc
2 Aug 23
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
7:37am
–
– Announces ~20% Workforce Reduction Enhancing Financial Strength; Further Reduces Full Year 2023 Non-GAAP R&D and SG&A Expense Guidance to $240 … and Medicaid rebates year over year.
R&D Highlights
Myelofibrosis
Initiated pivotal Phase 3 portion of the XPORT-MF-034 clinical trial (NCT04562389
8-K
EX-99.1
KPTI
Karyopharm Therapeutics Inc
4 May 23
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
7:53am
Million to $125 Million, Reflecting Increased Use of PAP –
– Non-GAAP R&D and SG&A Expense Guidance Revised to $245 Million to $260 Million; Company Re … regions.
R&D Highlights
Myelofibrosis (MF)
Updated results from the Phase 1 study evaluating the safety and efficacy of once-weekly selinexor
8-K
EX-99.1
hi5yufewqiqq 7yfbix
3 Nov 22
Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.1
psw377
4 Aug 22
Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
7:36am
8-K
EX-99.1
gmv5tneoeukvh4g1mymn
5 May 22
Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
7:09am
8-K
EX-10.2
r2dl9mz49lf lirys
29 Mar 22
Departure of Directors or Certain Officers
8:06am
8-K
EX-99.1
3xtt18fot5fyt5mx7tvt
8 Feb 22
Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
8:16am
8-K
EX-99.1
6xk x98xfogkfhmn16b
3 Nov 21
Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business
7:10am
8-K
EX-99.1
y5shcn8
5 Aug 21
Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results
7:11am
8-K
EX-99.1
dcj6jhykkvqayq9pn3sx
3 May 21
Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
7:20am
8-K
EX-99.1
i70c9s9
11 Feb 21
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
t5lp2d3cjxo4r6
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.1
kk230c
4 Aug 20
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
a0gj4z1cwkd96sb33
13 Feb 20
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
7:09am
8-K
EX-99.1
vx9oyh4ij0g6hbujgj
13 Jan 20
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
7:12am